Get More Information on Leukapheresis Market - Request Sample Report
The Leukapheresis Market Size was valued at USD 192 billion in 2023 and is expected to reach USD 491.05 billion by 2032 and grow at a CAGR of 11.01% over the forecast period 2024-2032.
The leukapheresis market is robustly growing because of the rising incidence of blood-related disorders and autoimmune diseases, technologies related to leukapheresis advanced in leaps and bounds, and demand for personalized medicine has increased widely. Blood disorders such as leukemia and lymphoma and autoimmune diseases such as rheumatoid arthritis and multiple sclerosis largely contribute to the growth of the market. According to The Leukemia & Lymphoma Society, in the United States, there are about 184,720 new cases of leukemia, lymphoma, or myeloma to be diagnosed in 2023. A Lancet study of May 2023 suggested that autoimmune conditions affect 1 in 10 and have growing prevalence with multifaceted issues, environmental, resulting in cases such as rheumatoid arthritis and type 1 diabetes. These statistics show an increasing number of patients demanding leukapheresis procedures.
Technological advancements propel the market growth further with new systems including automated devices, continuous flow centrifugation, and closed system devices that increase efficiency, safety, and yields of cell collection. For example, Terumo BCT's Spectra Optia Apheresis System in which the Spectra Optia is a mononuclear cell collection device that increases the safety and efficiency of cell therapy applications. Against this background, the American Society for Apheresis and other similar bodies established guidelines in October 2022 that updated leukapheresis protocols to optimize procedure quality across age ranges and research settings creating an avenue for industry development.
Other factors include a growing focus on personalized medicine, particularly for cell therapies such as CAR-T cell therapy and stem cell transplants, which are dependent on high-quality leukapheresis products for success. The highly complex regulation in the industry of leukapheresis means that high barriers to entry exist mainly in the form of very stringent requirements regarding matters such as safety and efficacy. However, the latter is likely to be stimulated by increasing demand due to growing conditions of blood and immune disorders. Companies like Haemonetics Corporation expand their global footprint through strategic partnering to penetrate emerging markets and support moderate regional growth. Despite relatively low levels of merger and acquisition activity, these factors collectively place the leukapheresis market to accelerate growth in the future.
Drivers
Rising Demand for Leukopaks in Immunotherapy and Oncology Research Fuels Leukapheresis Market Growth
The most significant driver of the leukapheresis market is the increasing demand for leukopaks in clinical research. Leukopaks are products of leukapheresis, rich in various types of immune cells such as lymphocytes, monocytes, and dendritic cells, and are used very critically in oncology, immunotherapy, and cell biology research. Due to their versatility and high concentration of immune cells, leukopaks are highly essential in a wide range of therapeutic and research applications, particularly in studies that require human cells.
With increasing activities from pharmaceutical and biotech companies towards cell-based immunotherapies, such as CAR-T therapy against leukemia, the demand for leukopaks is on the rise. CAR-T therapy utilizing T-cells derived from leukopaks for the generation of genetically modified chimeric antigen receptor T-cells has proved incredibly effective in the treatment of B-cell malignancies and multiple myeloma. As of today, nearly 300 pharmaceutical companies are actively involved in developing CAR-T therapy. ClinicalTrials.gov accounts for ongoing 316 CAR-T cell-related clinical trials within the United States up to August 2023, a sign that the interest in this type of therapy is growing as well as promising. Six CAR-T cell therapies have been approved through April 2023, owing to this groundbreaking efficacy. Nevertheless, these treatments carry risks like cytokine release syndrome and immune effector cell-associated neurotoxicity, which further reinforces the necessity for new methods while mitigating the risk in that particular segment. The need for such highly advanced immunotherapies and other research studies is likely to drive the leukapheresis market significantly.
Restraints
Risk of Complications and Adverse Effects
Therapeutic leukapheresis is associated with various complications, including decreased white blood cell (WBC) count, adverse reactions to anticoagulants, hypocalcemia, and potential risks of RBC or platelet loss. Such adverse effects can lead to dizziness, pain at the venipuncture site, and more severe complications in vulnerable patients, limiting the procedure's acceptance and usage.
Increased Risk for Patients with Underlying Conditions:
For donors with anemia, thrombocytopenia, or other underlying health issues, therapeutic leukapheresis poses significant risks, including pulmonary leukostasis and acute renal failure. These risks heighten concerns and serve as a deterrent in the market, particularly in cases where the potential for immune response complications is high.
By Product
The leukapheresis devices segment dominated the 2023 market and held the largest revenue share of 76.4%. The segment is further divided into centrifugation-based devices and membrane filtration-based devices. In centrifugation-based devices, there is going to be increased demand with the escalating level of blood disorders, such as leukemia and lymphoma, and more and more stem cell transplants to be done with technology speeding up advancement and efficiency and automation capabilities improving. Membrane filtration-based devices are also in demand due to increasing cases of autoimmune diseases and chronic illness, with the need for therapeutic apheresis and for depleting or recovering certain cell populations like white blood cells. In January 2023, the company StemExpress launched CellsExpress, which is meant to streamline research by providing bulk, customized isolated cell types from high-quality Leukopaks, thereby speeding up R&D processes. Further, these new product launches are anticipated to fuel up the demand for leukapheresis devices in the forecast period.
Leukapheresis disposables are expected to witness the fastest growth over the forecast period. This is due to enhanced procedure volume, greater awareness of blood component separation techniques, and stringent regulatory standards that focus more on patient safety. With the rise in the patient population with hematologic disorders and solid tumors, the number of procedures is also increasing due to the demand for disposables used in leukapheresis. For example, Haemonetics Corporation has a set of disposable kits that are compatible with the MCS+ system offered by the company to ensure effective cell collection and processing. The trend is likely to contribute to this market's growth during the forecast period.
By Application
Research applications accounted for the largest share of the market in 2023, with a revenue share of 67.9%. The growth in the application area is mainly because of the increasing interest in the development of novel therapies for diseases such as cancer and autoimmune disorders. Such research applications are expected to fuel growth in demand for leukapheresis procedures during the next forecast period as cells, such as T cells and stem cells, are isolated to further their study and therapeutic uses. For instance, the study in the journal Cancers, published in December 2023, highlighted the fact that emergency leukapheresis might improve the outcome and reduce the risk of early mortality among patients with acute myeloid leukemia and FLT3-ITD mutations more than leukocytosis.
The therapeutic application segment is set to grow at a compound annual growth rate of 11.51% over the forecast period. This growth is due to the increasing adoption of cell-based therapies and personalized medicine. A news article by Transfusion Medicine and Hemotherapy published in August 2022, stated that even if the patient population is smaller, therapeutic leukapheresis remains safe, effective, and available in the management of specific conditions.
In 2023, North America dominated the leukapheresis market with a revenue share of 36.96% due to its sophisticated healthcare infrastructure, high healthcare expenditure, and increasing prevalence of diseases like cancer and autoimmune disorders. The intense research and development activities coupled with the presence of major pharmaceutical and biotechnology companies with their interest in developing innovative treatments account for a significant contribution to the growth of the market in the region. Over the next few years, such factors are likely to sustain their momentum in this market. Improvements in healthcare technology and increased healthcare expenses will bear growth to this U.S. leukapheresis market. The leukapheresis procedure will gain wider acceptance by hospitals and other care settings, thus catalyzing further growth in the coming years.
The market is expected to grow rapidly in Europe as it involves greater expenditure on healthcare and improves awareness of therapeutic innovation. The technology of leukapheresis is going to be rapidly developed and adopted with collaborations between research institutions, pharmaceutical firms, and healthcare providers. The demand for leukapheresis is rising in the UK concerning incidence rates of blood cancers and autoimmune diseases. France will also experience high market growth, as research and development with positive government regulations regarding biotechnology and healthcare will continue. German segment is expected to have the fastest growth in that region primarily due to increased investments in new leukapheresis techniques and personalized medicine.
The Asia Pacific region is the fastest-growing region in the global leukapheresis market, with a CAGR of 12.2% from 2024 to 2032. Developing healthcare expenses, better infrastructure, and heightened awareness of advanced treatments are expected to fuel growth in this region. Amongst such countries, China, Japan, and India are going to experience strong growth, with investment in medical infrastructures and a higher prevalence of chronic diseases.
Need Any Customization Research On Leukapheresis Market - Inquiry Now
Charles River Laboratories International, Inc. – (Leukopaks)
Adacyte Therapeutics – (Leukopaks)
AllCells, LLC – (Fresh Leukopaks, Frozen Leukopaks)
Asahi Kasei Medical – (Cellsorba)
Haemonetics Corporation – (NexSys PCS, MCS+, PCS2)
Macopharma – (Leukokit)
Cerus Corporation – (INTERCEPT Blood System)
SB-Kawasumi Laboratories, Inc. – (Leukapheresis Kits)
StemExpress, LLC – (Clinical Grade Leukopaks)
Lonza Group AG – (Lovo Cell Processing System)
In March 2024, the FDA approved Bristol Myers Squibb’s Breyanzi, an innovative CAR T cell therapy for adult patients with specific types of leukemia and lymphoma. The treatment process begins with leukapheresis, where patients' white blood cells are collected to create the therapy.
In August 2023, the FDA approved the Reveos Automated Whole Blood Processing System by Terumo Blood and Cell Technologies. This system improves the efficiency of processing whole blood into white blood cells and other components, supporting efforts to increase the U.S. blood supply.
In May 2023, Akadeum Life Sciences launched a new product line for cell therapy research, advancing their BACS Microbubble technology. This innovation enables straightforward isolation of T cells and PBMCs from leukapheresis materials, eliminating the need for traditional lysis or centrifugation steps.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 192 billion |
| Market Size by 2032 | US$ 491.05 billion |
| CAGR | CAGR of 11.01% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Product [Leukapheresis Devices (Centrifugal Devices, Membrane Separators), Leukapheresis Disposables] •By Application [Research Application (Cancer Research, Immunology Research, Others), Therapeutics Application (Hematologic Disorders, Autoimmune Diseases, Others)] •By End-Use (Blood Centers, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Clinics) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Charles River Laboratories International, Inc., Adacyte Therapeutics, AllCells, LLC, Asahi Kasei Medical, Haemonetics Corporation, Macopharma, Cerus Corporation, SB-Kawasumi Laboratories, Inc., StemExpress, LLC, Lonza Group AG |
| Key Drivers | • Rising Demand for Leukopaks in Immunotherapy and Oncology Research Fuels Leukapheresis Market Growth |
| Restraints | • Risk of Complications and Adverse Effects • Increased Risk for Patients with Underlying Conditions |
Ans: The estimated compound annual growth rate is 11.01% during the forecast period for the Leukapheresis market.
Ans: The projected market value of the Leukapheresis market is estimated at USD 192 billion in 2023 and is expected to reach USD 491.05 billion by 2032.
Ans: Rising demand for leukopaks in immunotherapy and oncology research fuels leukapheresis market growth.
Ans: The risk of complications and adverse effects and increased risk for patients with underlying conditions are the restraints for the leukapheresis market.
Ans: North America is the dominant region with a 36.9% share in the Leukapheresis market.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Device Volume, by Region (2020-2032)
5.4 Healthcare Spending, by Region, (Government, Commercial, Private, Out-of-Pocket), 2023
5.5 Research & Development Trends in Leukapheresis (2023-2032)
5.6 Regulatory Approvals and Market Penetration (2023-2032)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Leukapheresis Market Segmentation, by Product
7.1 Chapter Overview
7.2 Leukapheresis Devices
7.2.1 Leukapheresis Devices Market Trends Analysis (2020-2032)
7.2.2 Leukapheresis Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.3 Centrifugal Devices
7.2.3.1 Centrifugal Devices Market Trends Analysis (2020-2032)
7.2.3.2 Centrifugal Devices Market Size Estimates and Forecasts to 2032 (USD Billion)
7.2.4 Membrane Separators
7.2.4.1 Membrane Separators Market Trends Analysis (2020-2032)
7.2.4.2 Membrane Separators Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Leukapheresis Disposables
7.3.1 Leukapheresis Disposables Market Trends Analysis (2020-2032)
7.3.2 Leukapheresis Disposables Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Leukapheresis Market Segmentation, by Application
8.1 Chapter Overview
8.2 Research Application
8.2.1 Research Application Market Trends Analysis (2020-2032)
8.2.2 Research Application Market Size Estimates and Forecasts to 2032 (USD Million)
8.2.3 Cancer Research
8.2.3.1 Cancer Research Market Trends Analysis (2020-2032)
8.2.3.2 Cancer Research Market Size Estimates and Forecasts to 2032 (USD Million)
8.2.4 Immunology Research
8.2.4.1 Immunology Research Market Trends Analysis (2020-2032)
8.2.4.2 Immunology Research Market Size Estimates and Forecasts to 2032 (USD Million)
8.2.5 Others
8.2.5.1 Others Market Trends Analysis (2020-2032)
8.2.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Therapeutics Application
8.3.1 Hematologic Disorders Market Trends Analysis (2020-2032)
8.3.2 Hematologic Disorders Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Autoimmune Diseases
8.4.1 Autoimmune Diseases Market Trends Analysis (2020-2032)
8.4.2 Autoimmune Diseases Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. Leukapheresis Market Segmentation, by End-Use
9.1 Chapter Overview
9.2 Blood Centers
9.2.1 Blood Centers Market Trends Analysis (2020-2032)
9.2.2 Blood Centers Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Academic & Research Institutes
9.3.1 Academic & Research Institutes Market Trends Analysis (2020-2032)
9.3.2 Academic & Research Institutes Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Pharmaceutical & Biotechnology Companies
9.4.1 Pharmaceutical & Biotechnology Companies Market Trends Analysis (2020-2032)
9.4.2 Pharmaceutical & Biotechnology Companies Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.4 North America Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.5 North America Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.6.2 USA Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.6.3 USA Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.7.2 Canada Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.7.3 Canada Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.2.8.2 Mexico Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.2.8.3 Mexico Leukapheresis Market Estimates and Forecasts, by End-Use(2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.4 Eastern Europe Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.5 Eastern Europe Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.6.2 Poland Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.6.3 Poland Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.7.2 Romania Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.7.3 Romania Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.8.2 Hungary Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.8.3 Hungary Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.9.2 Turkey Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.9.3 Turkey Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.4 Western Europe Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.5 Western Europe Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.6.2 Germany Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.6.3 Germany Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.7.2 France Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.7.3 France Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.8.2 UK Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.8.3 UK Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.9.2 Italy Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.9.3 Italy Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.10.2 Spain Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.10.3 Spain Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.11.2 Netherlands Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.11.3 Netherlands Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.12.2 Switzerland Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.12.3 Switzerland Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.13.2 Austria Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.13.3 Austria Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.4 Asia Pacific Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.5 Asia Pacific Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.6.2 China Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.6.3 China Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.7.2 India Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.7.3 India Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.8.2 Japan Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.8.3 Japan Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.9.2 South Korea Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.9.3 South Korea Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.10.2 Vietnam Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.10.3 Vietnam Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.11.2 Singapore Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.11.3 Singapore Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.12.2 Australia Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.12.3 Australia Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.4 Middle East Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.5 Middle East Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.6.2 UAE Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.6.3 UAE Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.7.2 Egypt Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.7.3 Egypt Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.9.2 Qatar Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.9.3 Qatar Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.4 Africa Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.5 Africa Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.6.2 South Africa Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.6.3 South Africa Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.7.2 Nigeria Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.7.3 Nigeria Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Leukapheresis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.4 Latin America Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.5 Latin America Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.6.2 Brazil Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.6.3 Brazil Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.7.2 Argentina Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.7.3 Argentina Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.8.2 Colombia Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.8.3 Colombia Leukapheresis Market Estimates and Forecasts, by End-Use(2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Leukapheresis Market Estimates and Forecasts, by Product (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America Leukapheresis Market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America Leukapheresis Market Estimates and Forecasts, by End-Use (2020-2032) (USD Million)
11. Company Profiles
11.1 Lonza Group AG
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 StemExpress, LLC
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 SB-Kawasumi Laboratories, Inc.
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Cerus Corporation
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Macopharma
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Haemonetics Corporation
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Asahi Kasei Medical
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 AllCells, LLC
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Adacyte Therapeutics
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Charles River Laboratories International, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Product
Leukapheresis Devices
Centrifugal Devices
Membrane Separators
Leukapheresis Disposables
By Application
Research Application
Cancer Research
Immunology Research
Others
Therapeutics Application
Hematologic Disorders
Autoimmune Diseases
Others
By End-Use
Blood Centers
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Hospitals & Clinics
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The HLA Typing Market size was estimated at USD 1.59 billion in 2023 and is expected to reach USD 2.84 billion by 2032 at a CAGR of 6.6% during the forecast period of 2024-2032.
The Neuroscience Market Size was valued at USD 35.3 billion in 2023 and is expected to reach USD 50.2 Billion by 2032, at 4.00% CAGR by 2024-2032
The Nucleotide Market Size was valued at USD 0.83 Billion in 2023, and is expected to reach USD 1.61 Billion by 2032, and grow at a CAGR of 8.01% over the forecast period 2024-2032.
The Vitrification Market Size, valued at USD 8.23 billion in 2023, is projected to reach USD 33.04 billion by 2032, growing at a CAGR of 16.75%.
The Infertility Treatment Market Size was USD 1.745 billion in 2023 & is expected to reach USD 3.512 Bn by 2032, growing at a CAGR of 8.02% from 2024-2032.
The Biodegradable Medical Plastics Market Size was valued at USD 1.7 Bn in 2023 and will reach USD 4.5 Bn by 2032 and grow at a CAGR of 11.5% Over the Forecast Period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
